



87 Comparison of mutational changes in involved N1 lymph nodes with those
in primary tumors in stage II nonsmall cell lung cancer: A pilot study
Hiran C. Fernando, FRCS, FRCSEd, Eizaburo Sasatomi, MD, Neil A. Christie, FRCS(C),
Percival O. Buenaventura, MD, Sydney D. Finkelstein, MD, Samuel A. Yousem, MD,
Ryan Soose, John M. Close, MA, PMSD, and James D. Luketich, MD, Pittsburgh, Pa
The loss of heterozygosity in primary tumor (PT) and lymph node metastases of patients with
resected stage II nonsmall cell lung cancer was studied. Patients were stratified into risk
groups on the basis of the severity of mutations in lymph node metastases compared with those
in primary tumor metastases. Low-risk patients in the adenocarcinoma subset demonstrated
superior survival.
92 Down-regulation of beta catenin inhibits the growth of esophageal carcinoma
cells
Nirmal K. Veeramachaneni, MD, Hirotoshi Kubokura, MD, PhD, Li Lin, MD,
James A. Pippin, BA, G. Alexander Patterson, MD, Jeffrey A. Drebin, MD, PhD, and
Richard J. Battafarano, MD, PhD, St Louis, Mo
Beta catenin, the effector of the Wnt signaling pathway, plays a role in the pathogenesis of
human esophageal cancer. We describe the inhibition of esophageal cancer cell growth by
down-regulation of beta catenin using phophorothioate antisense oligonucleotides specific to
beta catenin.
99 Idiopathic laryngotracheal stenosis: Effective definitive treatment with
laryngotracheal resection Œ
Simon K. Ashiku, MD, Akin Kuzucu, MD, Hermes C. Grillo, MD, Cameron D. Wright, MD,
John C. Wain, MD, Bruce Lo, MD, and Douglas J. Mathisen, MD, Boston, Mass
Idiopathic laryngotracheal stenosis is an entity that occurs almost exclusively in women and is
without known cause. It is not a progressive process, but the timing of the operation is crucial.
Single-staged laryngotracheal resection is successful in restoring the airway while preserving
voice quality in more than 90% of patients. Protective tracheostomy is now rarely required
(1/30). Long-term follow-up shows a stable airway and improvement in voice quality.
108 Two commonly used neoadjuvant chemoradiotherapy regimens for locally
advanced stage III nonsmall cell lung carcinoma: Long-term results and
associations with pathologic response
Mitchell Machtay, MD, Jason H. Lee, MD, James P. Stevenson, MD, Joseph B. Shrager, MD,
Kenneth M. Algazy, MD, Joseph Treat, MD, and Larry R. Kaiser, MD, Philadelphia, Pa, and
Fall River, Mass
Neoadjuvant concurrent chemoradiation delivers high resectability, a major pathologic response
rate, and local-regional control, with encouraging long-term survival considering the patient
population studied. Major pathologic response correlates with long-term survival. Neoadjuvant
carboplatin/paclitaxel/radiotherapy is an appropriate framework on which to add new therapies.
Table of Contents (continued)
(continued on page 18A)
16A The Journal of Thoracic and Cardiovascular Surgery ● January 2004
ED
ITO
RIA
L
CSP
G
TS
A
CD
ET
CH
D
